Renal tolerance of rubidium chloride: short-term clinical evaluation.
The rubidium and lithium ions are known to have opposite effects on a wide range of biochemical and behavioral parameters in experimental animals. Based on the proven effectiveness of lithium as an antimanic agent, several trials have been conducted with rubidium in the acute treatment of the depressive phase of bipolar illness. The results to date are promising. However, the 30- to 60-day biologic half-life of rubidium has mandated careful studies of potential toxicity before engaging in long-term administration of this ion to depressive subjects. One area of potential concern is the possibility of renal toxicity, which could be expressed as unexpectedly increased retention of rubidium. The data in this paper show that after 15 days of rubidium administration, there are no changes beyond the normal range in a variety of kidney function tests, including in four enzymes which are specific markers of tubule cell function.
Tuoni
M
M
Clinical Medical Institute, University of Pisa, Italy.
Marchitiello
M
M
Paternoster
G
G
Gerace
S
S
Palla
R
R
Placidi
G F
GF
Lenzi
A
A
Toschi
D
D
Meltzer
H L
HL
D000368:Aged; D002712:Chlorides / Q000009:adverse effects*; D003404:Creatinine / Q000652:urine; D004573:Electrolytes / Q000652:urine; D004798:Enzymes / Q000652:urine; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D008875:Middle Aged; D012413:Rubidium / Q000009:adverse effects*; D014508:Urea / Q000652:urine; D014527:Uric Acid / Q000652:urine
D002712:Chlorides; D004573:Electrolytes; D004798:Enzymes; D014527:Uric Acid; D014508:Urea; D003404:Creatinine; D012413:Rubidium; C032710:rubidium chloride